SCHEMBL5382502

SCHEMBL5382502

Cc1cc(OC2CN(C3CCCCC3)C2)n2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.41
MAPK1 P28482 2/20 0.41
MAPT P10636 4/20 0.38
CNR2 P34972 2/20 0.38
CNR1 P21554 1/20 0.38
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
ALDH1A1 P00352 4/20 0.37
CRHR1 P34998 2/20 0.37
POLB P06746 2/20 0.36
GPR55 Q9Y2T6 1/20 0.35
HTT P42858 2/20 0.35
HPGD P15428 3/20 0.35
RAB9A P51151 3/20 0.35
TP53 P04637 1/20 0.35
KDM4E B2RXH2 3/20 0.34
THRB P10828 1/20 0.34
NPC1 O15118 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833058 0.87 CNR1 (0.38) HSD17B10MAPK1CNR2CNR1HPGD
SCHEMBL5375132 0.87 CNR1 (0.40) MAPK1MAPTCNR2CNR1KMT2A
SCHEMBL5617459 0.86 CNR1 (0.37) MAPTCNR2CNR1KMT2ANPC1
SCHEMBL5380243 0.82 ALDH1A1 (0.41) MAPK1MAPTCNR2CNR1KMT2A
SCHEMBL5375929 0.78 MAPT (0.45) MAPK1MAPTCNR2CNR1KMT2A
SCHEMBL5375242 0.76 MAPT (0.64) MAPK1MAPTCNR2CNR1KMT2A
SCHEMBL14577345 0.76 MEN1 (0.62) HSD17B10MAPK1MAPTCNR2CNR1
SCHEMBL5391337 0.74 MAPT (0.49) MAPK1MAPTCNR2CNR1KMT2A
SCHEMBL4841026 0.72 CNR2 (0.39) MAPTCNR2CNR1CRHR1TP53
SCHEMBL5380598 0.72 KMT2A (0.48) HSD17B10MAPK1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US claimed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US claimed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 HSD17B10 2817/4885MAPK1 1959/4885MAPT 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.